Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827261) titled 'A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Condition:
Non-small Cell Lung Cancer
Intervention:
Drug: BL-B01D1
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 2026
Target Sample Size: 36
Countries of Recruitment:
China
To know more, visit https:/...